X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6452) 6452
Book Review (436) 436
Publication (226) 226
Newsletter (31) 31
Book Chapter (9) 9
Conference Proceeding (9) 9
Dissertation (2) 2
Data Set (1) 1
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5896) 5896
humans (3872) 3872
cytarabine - pharmacology (3712) 3712
animals (2464) 2464
female (1591) 1591
male (1516) 1516
oncology (1473) 1473
mice (1294) 1294
cytarabine - administration & dosage (1229) 1229
cytarabine (971) 971
adult (967) 967
middle aged (964) 964
antineoplastic combined chemotherapy protocols - therapeutic use (789) 789
cell line (751) 751
hematology (743) 743
pharmacology & pharmacy (732) 732
antineoplastic agents - pharmacology (713) 713
cytarabine - therapeutic use (711) 711
leukemia, myeloid, acute - drug therapy (679) 679
aged (673) 673
cells, cultured (673) 673
chemotherapy (606) 606
time factors (575) 575
dose-response relationship, drug (540) 540
adolescent (514) 514
cancer (501) 501
leukemia (494) 494
cell division - drug effects (473) 473
kinetics (466) 466
cell survival - drug effects (464) 464
apoptosis (454) 454
rats (449) 449
acute myeloid-leukemia (443) 443
antimetabolites, antineoplastic - pharmacology (435) 435
cytarabine - metabolism (431) 431
apoptosis - drug effects (420) 420
tumor cells, cultured (417) 417
drug synergism (390) 390
treatment outcome (382) 382
acute myelogenous leukemia (381) 381
dna - biosynthesis (375) 375
child (360) 360
cell line, tumor (352) 352
hydroxyurea - pharmacology (341) 341
drug resistance (335) 335
leukemia, myeloid, acute - pathology (330) 330
ara-c (327) 327
cytarabine - adverse effects (325) 325
acute myeloid leukemia (321) 321
therapy (320) 320
tritium (320) 320
cytosine-arabinoside (316) 316
acute disease (309) 309
biochemistry & molecular biology (300) 300
antineoplastic agents - therapeutic use (294) 294
cytarabine - analogs & derivatives (294) 294
thymidine - metabolism (294) 294
leukemia - drug therapy (278) 278
abridged index medicus (275) 275
expression (273) 273
antineoplastic combined chemotherapy protocols - adverse effects (269) 269
remission induction (267) 267
cell differentiation - drug effects (265) 265
dna replication - drug effects (256) 256
drug resistance, neoplasm (255) 255
cells (254) 254
prognosis (251) 251
dactinomycin - pharmacology (242) 242
child, preschool (239) 239
cytosine arabinoside (233) 233
cell biology (232) 232
leukemia, myeloid - drug therapy (230) 230
research (226) 226
cycloheximide - pharmacology (224) 224
etoposide - administration & dosage (222) 222
cell cycle - drug effects (220) 220
in vitro techniques (219) 219
leukemia, myeloid, acute - metabolism (216) 216
drug administration schedule (214) 214
tumor cells, cultured - drug effects (214) 214
methotrexate - pharmacology (211) 211
medicine & public health (210) 210
methotrexate - administration & dosage (210) 210
mutation (207) 207
daunorubicin - administration & dosage (203) 203
daunorubicin - pharmacology (202) 202
cricetinae (201) 201
antineoplastic combined chemotherapy protocols - administration & dosage (199) 199
cytarabine - toxicity (197) 197
dna damage (197) 197
antineoplastic combined chemotherapy protocols - pharmacology (190) 190
phosphorylation (188) 188
cytarabine - pharmacokinetics (187) 187
doxorubicin - pharmacology (187) 187
in-vitro (187) 187
hl-60 cells (185) 185
acute lymphoblastic-leukemia (182) 182
dna (182) 182
flow cytometry (182) 182
aml (180) 180
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6199) 6199
Japanese (75) 75
Chinese (49) 49
German (47) 47
Russian (46) 46
French (31) 31
Spanish (17) 17
Italian (13) 13
Polish (6) 6
Czech (2) 2
Bulgarian (1) 1
Danish (1) 1
Portuguese (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2012, Volume 11, Issue 2, pp. 427 - 438
Journal Article
Cell, ISSN 0092-8674, 06/2012, Volume 149, Issue 6, pp. 1284 - 1297
Journal Article
Cell Cycle, ISSN 1538-4101, 05/2012, Volume 11, Issue 9, pp. 1851 - 1861
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2015, Volume 14, Issue 10, pp. 2364 - 2373
Journal Article
Phytomedicine, ISSN 0944-7113, 01/2015, Volume 22, Issue 1, pp. 213 - 222
Journal Article
Molecular and Cellular Biology, ISSN 0270-7306, 07/2001, Volume 21, Issue 13, pp. 4129 - 4139
Journal Article
Blood, ISSN 0006-4971, 04/2001, Volume 97, Issue 7, pp. 1999 - 2007
Journal Article
BMC Pharmacology and Toxicology, ISSN 2050-6511, 06/2013, Volume 14, Issue 1, pp. 32 - 32
Background: Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to high RNA synthesis, including synthesis of... 
Dormancy | Leukemia | RNA polymerase II inhibitors | PROGENITOR CELLS | CYTOSINE-ARABINOSIDE | COLONY-STIMULATING FACTOR | TRANSCRIPTION | DOWN-REGULATION | MYELOBLASTIC-LEUKEMIA | P-GLYCOPROTEIN | R-ROSCOVITINE | HEMATOPOIETIC STEM-CELLS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | FLAVOPIRIDOL | Cytarabine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Adenine Nucleotides - pharmacology | Apoptosis - drug effects | Humans | Leukemia, Myeloid - genetics | Daunorubicin - pharmacology | RNA Polymerase II - metabolism | RNA, Neoplasm - metabolism | Heterocyclic Compounds, 4 or More Rings - pharmacology | Dose-Response Relationship, Drug | Leukemia, Myeloid - pathology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Piperidines - pharmacology | Antineoplastic Agents - pharmacology | Flavonoids - pharmacology | Cell Survival - drug effects | Acute Disease | RNA Polymerase II - antagonists & inhibitors | Purines - pharmacology | Enzyme Inhibitors - pharmacology | Etoposide - pharmacology | Arabinonucleosides - pharmacology | Sirolimus - pharmacology | Azacitidine - pharmacology | Leukemia, Myeloid - metabolism | Cell Line, Tumor | RNA, Neoplasm - genetics | Anthracyclines | Synthesis | RNA | Heterocyclic compounds | Analysis | Physiological aspects | Etoposide | Apoptosis | DNA | Nucleosides | Flow cytometry | Phosphorylation | Bone marrow | Kinases | Gene expression | Experiments | Cancer therapies | Patients | Pharmaceuticals | Cancer | Index Medicus
Journal Article
Veterinary and Comparative Oncology, ISSN 1476-5810, 06/2019, Volume 17, Issue 2, pp. 165 - 173
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2007, Volume 25, Issue 1, pp. 31 - 40
Journal Article
Blood, ISSN 0006-4971, 04/1997, Volume 89, Issue 8, pp. 2959 - 2965
It is vital to develop effective therapy for children with acute lymphoblastic leukemia (ALL), in whom no remission occurs or who suffer relapse with current... 
INVITRO CHEMOSENSITIVITY | K MA HEMATOLOGY | CELLS | IN-VITRO | GROWTH | CLINICAL PROGNOSIS | RESISTANCE PROFILES | HEMATOLOGY | EXPRESSION | MTT ASSAY | IMMUNOPHENOTYPE | CHILDREN | Recurrence | Vincristine - pharmacology | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Neoplastic Stem Cells - drug effects | Humans | Aclarubicin - administration & dosage | Child, Preschool | Drug Resistance, Neoplasm | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Asparaginase - pharmacology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Dexamethasone - pharmacology | Neoplastic Stem Cells - pathology | Vincristine - administration & dosage | Melphalan - pharmacology | Child | Daunorubicin - administration & dosage | Infant, Newborn | Dexamethasone - administration & dosage | Tumor Cells, Cultured - drug effects | Etoposide - pharmacology | Etoposide - administration & dosage | Bleomycin - administration & dosage | Prednisolone - pharmacology | Remission Induction | Cytarabine - administration & dosage | Mitomycin - pharmacology | Cyclophosphamide - pharmacology | Adolescent | Bleomycin - pharmacology | Methotrexate - administration & dosage | Mitoxantrone - pharmacology | Mitomycin - administration & dosage | Methotrexate - pharmacology | Cyclophosphamide - analogs & derivatives | Cytarabine - pharmacology | Prognosis | Daunorubicin - pharmacology | Infant | Life Tables | Dose-Response Relationship, Drug | Doxorubicin - analogs & derivatives | Antineoplastic Agents - pharmacology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Doxorubicin - administration & dosage | Cell Survival | Asparaginase - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Aclarubicin - pharmacology | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Index Medicus | Abridged Index Medicus
Journal Article
STEM CELLS, ISSN 1066-5099, 07/2017, Volume 35, Issue 7, pp. 1835 - 1848
Myelotoxic injury, such as chemotherapeutic agents and ionizing radiation, unlocks the vigorous power of hematopoietic stem cells (HSCs) to replenish the... 
Adipose | Proliferation | Cytotoxic agents | Adult haematopoietic stem cells | Cell cycle | HOMEOSTASIS | PHOSPHORYLATION | REGENERATION | BONE-MARROW NICHE | SELF-RENEWAL | CHEMOTHERAPY | CELL & TISSUE ENGINEERING | CELL BIOLOGY | 5-FLUOROURACIL | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | LEUKEMIA-INITIATING CELLS | INSULIN-RESISTANCE | IN-VIVO | HEMATOLOGY | Myeloablative Agonists - pharmacology | Whole-Body Irradiation | Cytarabine - pharmacology | Bone Marrow - radiation effects | Hematopoiesis - drug effects | Hematopoiesis - radiation effects | Mechanistic Target of Rapamycin Complex 1 - genetics | Epoxy Compounds - pharmacology | Adiponectin - genetics | Bone Marrow - metabolism | Adiponectin - deficiency | Bone Marrow Transplantation | Bone Marrow - drug effects | Poly I-C - pharmacology | Signal Transduction | Gene Expression Regulation | Hematopoiesis - genetics | Hematopoietic Stem Cells - metabolism | Sirolimus - pharmacology | Mechanistic Target of Rapamycin Complex 1 - metabolism | Mice, Knockout | Animals | Bone Marrow - pathology | Cyclophosphamide - pharmacology | Hematopoietic Stem Cells - cytology | Benzhydryl Compounds - pharmacology | Fluorouracil - pharmacology | Mice | Chemotherapy | Ionizing radiation | Hematopoietic stem cells | Cancer | TOR protein | Cell proliferation | Potentiation | Intervention | Adipose tissue | Stem cell transplantation | Activation | Adipocytes | Recovery | Adiponectin | Rodents | Bone marrow | Radiation injuries | Diffusion | Injuries | Recombinant | Rapamycin | Inflammation | Mammals | Ablation | Stem cells | Bursting | Hematopoietic system | In vitro methods and tests | Granulopoiesis | Index Medicus
Journal Article
Leukemia Research, ISSN 0145-2126, 2009, Volume 34, Issue 4, pp. 535 - 541
Abstract We have previously shown that inhibition of translation initiation, using the small molecule inhibitor silvestrol, induces apoptosis in a pre-clinical... 
Hematology, Oncology and Palliative Medicine | AML | Chemotherapy | Silvestrol | Synergy | Translation initiation | THERAPEUTIC SUPPRESSION | APOPTOSIS | ACTIVATION | MCL-1 | DOWN-REGULATION | ACUTE MYELOID-LEUKEMIA | BH3 MIMETIC ABT-737 | MESSENGER-RNAS | IN-VITRO | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOLOGY | Piperazines - administration & dosage | Cytarabine - pharmacology | Triterpenes - pharmacology | Humans | Leukemia, Myeloid, Acute - metabolism | Daunorubicin - pharmacology | Cytotoxins - administration & dosage | Protein Synthesis Inhibitors - administration & dosage | Cytotoxins - pharmacology | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | U937 Cells | Leukemia, Myeloid, Acute - drug therapy | Protein Synthesis Inhibitors - pharmacology | Drug Evaluation, Preclinical | Peptide Initiation Factors - antagonists & inhibitors | Daunorubicin - administration & dosage | Etoposide - pharmacology | Etoposide - administration & dosage | Nitrophenols - administration & dosage | Sulfonamides - pharmacology | Piperazines - pharmacology | Cytarabine - administration & dosage | Drug Synergism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Biphenyl Compounds - administration & dosage | Cell Line, Tumor | HL-60 Cells | Protein Biosynthesis - drug effects | Triterpenes - administration & dosage | Sulfonamides - administration & dosage | Anthracyclines | RNA | University and college libraries | Analysis | Etoposide | Protein biosynthesis | Lymphomas | Index Medicus
Journal Article